Audiogenic seizures in magnesium-deficient mice: effects of magnesium pyrrolidone-2-carboxylate, magnesium acetyltaurinate, magnesium chloride and vitamin B-6.
Magnesium deficiency in mice causes and increases audiogenic seizures. This effect was reversed by oral administration of magnesium acetyltaurinate (ATaMg), magnesium pyrrolidone-2-carboxylate (PCMH), MgCl2. When treatment was discontinued, audiogenic seizures recurred only in the groups treated with PCMH or MgCl2. Following intraperitoneal administration of AtaMg, the mice were protected against audiogenic seizures after 4 h and this protection persisted for up to 72 h after the treatment. With the other magnesium salts (PCMH and MgCl2) maximum protection occurred by 6 h after the injection, but after that time the number of seizures increased sharply. Intraperitoneal taurine alone only reduced the severity of the audiogenic seizures. The length of treatment needed to inhibit audiogenic seizures was reduced by treatment with a combination of vitamin B-6 (a magnesium fixing agent) and PCMH or MgCl2. However this combination of vitamin B-6 and magnesium salts did not prevent the recurrence of audiogenic seizures, which was only achieved by ATaMg. The results suggest that audiogenic seizures in magnesium-deficient mice form a model of magnesium depletion. This depletion is completely inhibited by the combination of an inhibitory neurotransmitter (taurine) and magnesium, in the form of magnesium acetyltaurinate.
Bac
P
P
S.D.R.M. Hôpital Saint-Vincent de Paul, Paris, France.
Herrenknecht
C
C
Binet
P
P
Durlach
J
J
D000161:Acoustic Stimulation; D000818:Animals; D004032:Diet; D007275:Injections, Intravenous; D008274:Magnesium / Q000008:administration & dosage; D015636:Magnesium Chloride / Q000008:administration & dosage / Q000627:therapeutic use*; D008275:Magnesium Deficiency / Q000150:complications*; D008297:Male; D051379:Mice; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D012640:Seizures / Q000209:etiology* / Q000517:prevention & control; D013654:Taurine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015636:Magnesium Chloride; C083076:acetyltaurine; D013654:Taurine; D008274:Magnesium; D011736:Pyridoxine; D011761:Pyrrolidonecarboxylic Acid